Galapagos Reports a Net Profit of 320.9 Million Euros in 2025 and Anticipates Cash Neutrality by End of 2026
On Monday, biotechnology group Galapagos released its financial results for the year 2025, marked by a dramatic recovery in net income due to the release of deferred revenues for its drug discovery platform. Simultaneously, the group confirmed its strategic refocus on immunology and oncology, moving away from its cell therapy operations.
Financial Performance and Strategic Decisions
Galapagos recorded a net profit of 320.9 million euros in 2025, up from 74.1 million euros in 2024. This performance was primarily due to the release of 1,069.0 million euros in revenues corresponding to the balance of deferred revenues allocated to the drug discovery platform. The group posted an operating result of 295.1 million euros in 2025, compared to an operating loss of 188.3 million euros in 2024. However, this improvement masks the significant impact of strategic decisions made during the year. The discontinuation of cell therapy activities resulted in expenses of 275.0 million euros, including an impairment of 228.1 million euros on goodwill and fixed assets, severance costs of 33.3 million euros, termination fees of collaborations amounting to 16.3 million euros, and miscellaneous expenses of 27.6 million euros, partially offset by a favorable adjustment of 21.8 million euros in contingent consideration payable. The strategic reorganization of small molecule activities announced in January 2025 generated additional charges of 124.8 million euros, divided among severance costs of 47.7 million euros, termination fees of collaborations of 46.1 million euros, impairment of fixed assets of 9.5 million euros, and ancillary expenses of 21.5 million euros.
Cash Position and Projections
As of December 31, 2025, Galapagos had cash and financial investments totaling 2,998.0 million euros, down from 3,317.8 million euros a year earlier. This net decrease of 319.8 million euros results from several factors: an operational cash burn of 189.1 million euros, foreign exchange losses of 128.3 million euros, the provision of a convertible loan of 20.0 million euros to a third party, partially offset by a net inflow of 17.6 million euros related to the sale or acquisition of subsidiaries. The group anticipates cash neutrality by the end of 2026, excluding commercial development activities and currency fluctuations. Galapagos expects its cash balance to be between 2,775.0 million euros and 2,850.0 million euros as of December 31, 2026. For 2026, the group anticipates a negative cash flow of approximately 50.0 million euros in the first quarter due to the discontinuation of cell therapy activities, followed by restructuring charges of 125.0 to 175.0 million euros throughout the year, a reduction of 25.0 million euros compared to previous guidance. The costs of implementing the restructuring of small molecules are estimated at 35.0 to 40.0 million euros, while the TYK2 program is expected to incur costs of up to 40.0 million euros.
Performance of Discontinued Operations
The net profit from discontinued operations related to Jyseleca was limited to 1.4 million euros in 2025, down from 75.4 million euros in 2024. This decrease reflects the realization in 2024 of a gain of 52.3 million euros from the sale of the product to Alfasigma, which had no equivalent in 2025. Net financial income amounted to 5.8 million euros, compared to 185.2 million euros in 2024. The group recorded a tax income of 18.6 million euros in 2025, compared to 1.8 million euros in 2024, mainly due to the cancellation of deferred tax liabilities related to intangible assets of cell therapy following their impairment.
